Hikaru Samejima - Terumo Corp President
| TRUMY Stock | USD 19.97 0.42 2.06% |
President
Hikaru Samejima is Executive Officer and Presidentident of Interventional Systems Business in Cardiovascular Company of Terumo Corp ADR since 2018.
| Tenure | 6 years |
| Phone | 81 3 3374 8111 |
| Web | https://www.terumo.co.jp |
Terumo Corp Management Efficiency
The company has return on total asset (ROA) of 0.0441 % which means that it generated a profit of $0.0441 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0763 %, meaning that it generated $0.0763 on every $100 dollars invested by stockholders. Terumo Corp's management efficiency ratios could be used to measure how well Terumo Corp manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Brian Andrews | The Cooper Companies, | 45 | |
| Stewart Strong | Haemonetics | 57 | |
| Agostino Ricupati | The Cooper Companies, | 57 | |
| Jennifer Schneiders | Hologic | 56 | |
| Holly Sheffield | The Cooper Companies, | 53 | |
| Roy Galvin | Haemonetics | 54 | |
| Daniel McBride | The Cooper Companies, | 56 | |
| Jacqueline Scanlan | Haemonetics | 46 | |
| Howard Yu | Envista Holdings Corp | 51 | |
| Jeffrey Kappler | Envista Holdings Corp | 41 | |
| Patrik Eriksson | Envista Holdings Corp | 56 | |
| Jan Verstreken | Hologic | 56 | |
| James Darecca | Haemonetics | 50 | |
| Robert Auerbach | The Cooper Companies, | 58 | |
| Virginia Sanzone | ICU Medical | 49 | |
| William Burke | Haemonetics | 52 | |
| Michelle Basil | Haemonetics | 52 | |
| Daniel Woolson | ICU Medical | 47 | |
| Randal Golden | The Cooper Companies, | 57 | |
| Anila Lingamneni | Haemonetics | 57 | |
Management Performance
| Return On Equity | 0.0763 | |||
| Return On Asset | 0.0441 |
Terumo Corp ADR Leadership Team
Elected by the shareholders, the Terumo Corp's board of directors comprises two types of representatives: Terumo Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Terumo. The board's role is to monitor Terumo Corp's management team and ensure that shareholders' interests are well served. Terumo Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Terumo Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Toshiaki Takagi, Senior Executive Officer, Director | ||
| Kazunori Hirose, Executive Officer, Vice President of Base Medical Device Business Operation Unit in Hospital Company | ||
| Shoji Hatano, Senior Executive Officer, Manager of Business Planning Office | ||
| Hikaru Samejima, Executive Officer and Presidentident of Interventional Systems Business in Cardiovascular Company | ||
| Naoki Muto, Chief Officer | ||
| Miho Mizuguchi, Executive Officer, Chief Legal Officer, Manager of Legal & Compliance Office | ||
| Fumihisa Hirose, Executive Officer, Senior Vice President of Cardiovascular Company | ||
| Tsuyoshi Tomita, Senior Executive Officer, Vice President of Hospital Company, Manager of Earnings Recovery Office in Hospital Company and Presidentident of DM & Health Care Business in Hospital Company | ||
| Shinjiro Sato, Senior Executive Officer, Director | ||
| Kyo Nishikawa, Executive Officer and Presidentident of Subsidiary |
Terumo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Terumo Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0763 | |||
| Return On Asset | 0.0441 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 21.89 B | |||
| Shares Outstanding | 734.2 M | |||
| Price To Earning | 31.08 X | |||
| Price To Book | 2.52 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 703.3 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Terumo Pink Sheet Analysis
When running Terumo Corp's price analysis, check to measure Terumo Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Terumo Corp is operating at the current time. Most of Terumo Corp's value examination focuses on studying past and present price action to predict the probability of Terumo Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Terumo Corp's price. Additionally, you may evaluate how the addition of Terumo Corp to your portfolios can decrease your overall portfolio volatility.